The development of effective vaccines and therapies for human parainfluenza virus (HPIV) infections is a complex but vital endeavor. By leveraging our expertise and state-of-the-art facilities, our company is poised to lead the charge in HPIV vaccine and therapy development.
Overview of Human Parainfluenza Virus Infection
Human parainfluenza virus (HPIV) infections play a significant role in respiratory illnesses across all age groups, particularly in young children, the elderly, and immunocompromised individuals. HPIVs are enveloped, single-stranded RNA viruses belonging to the Paramyxoviridae family, classified into four major types: HPIV-1, HPIV-2, HPIV-3, and HPIV-4. These viruses primarily cause respiratory tract infections, leading to conditions such as croup, bronchitis, and pneumonia. HPIV infections are responsible for a substantial proportion of hospitalizations in children under five, second only to respiratory syncytial virus (RSV).
Fig.1 Schematic diagram of parainfluenza virus 5 (PIV5) genomes and virus rescue. (Chen Z., et al., 2018)
Vaccine Development for Human Parainfluenza Virus Infection
Live-Attenuated Vaccines
Live-attenuated vaccines contain a weakened form of the virus, which is unable to cause disease but can still replicate and stimulate an immune response. Examples include the bovine PIV-3 (bPIV-3) vaccine, which has shown promise in clinical trials for its safety and ability to generate an immune response.
Recombinant Vaccines
Recombinant DNA technology has facilitated the development of vaccines that express specific antigens of HPIV. The rHPIV3cp45 vaccine, for example, is a cDNA-derived candidate that has undergone phase I trials, demonstrating safety and immunogenicity in infants and young children.
Quadrivalent Vaccines
The goal of quadrivalent vaccines is to provide broad protection against all four types of human parainfluenza virus (HPIV). These vaccines involve the engineering of the viral fusion (F) glycoprotein into a prefusion state, which has been shown to elicit higher neutralizing antibody responses.
Therapeutics Development for Human Parainfluenza Virus Infection
Ribavirin, a nucleoside analogue, has been used off-label for the therapeutics of severe HPIV infections, particularly in immunocompromised hosts. While it has shown some efficacy, its use is limited by concerns over safety and the need for aerosolized administration.
DAS181 is a novel sialidase fusion protein that inhibits the initial attachment of HPIV to host cells by targeting the viral hemagglutinin-neuraminidase (HN) protein. It has demonstrated promise in treating severe HPIV infections in clinical trials, offering a non-viral targeted approach to therapy.
Our Services
Specializing in the holistic advancement of vaccines and therapies for HPIV infections, our company utilizes cutting-edge scientific research and state-of-the-art technologies to formulate solutions that cater to the unmet requirements within this domain.
Disease Models
- IFNα/β and IFNγ Double Knockout Models (AG129 Mice)
- Hamster HPIV-3 Infection Models
- Guinea Pig Respiratory Tract Infection Models
- Cotton Rat HPIV Infection Models
Our
preclinical research services are tailored to address the unique challenges associated with the HPIV vaccine and therapy development. We offer a range of services, including:
- Immunogenicity Studies: Evaluating the immune response elicited by vaccine candidates in animal models to assess their potential efficacy.
- Safety Assessments: Conducting comprehensive safety evaluations to ensure the well-being of subjects during vaccine trials.
- Pharmacodynamics and Pharmacokinetics: Investigating the mechanisms of action and distribution of antiviral therapies to optimize dosing regimens.
- Pathogenesis Studies: Understanding the viral pathogenesis of HPIV to inform vaccine and therapeutic strategies.
If you are interested in our services, please feel free to
contact us.
References
- Chen, Zhenhai. "Parainfluenza virus 5–vectored vaccines against human and animal infectious diseases." Reviews in medical virology 28.2 (2018): e1965.
- Pawełczyk, Malgorzata, and Marek Leszek Kowalski. "The role of human parainfluenza virus infections in the immunopathology of the respiratory tract." Current allergy and asthma reports 17 (2017): 1-10.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
